{"pub": "wsj", "url": "https://marketwatch.com/story/johnson-johnson-restates-earnings-over-opioid-settlement-2019-10-23?mod=rsswn", "downloaded_at": "2019-10-23 23:23:51.370163+00:00", "title": "Johnson & Johnson restates earnings over opioid settlement", "language": "en", "text": "Johnson & Johnson Inc. JNJ, +0.54% said it lowered its September-ending earnings to account for opioid litigation, according to a Securities and Exchange Commission filing late Wednesday. The company said it lowered fiscal third-quarter earnings to $1.8 billion, or 66 cents a share, from a previously reported $4.8 billion, or $1.81 a share. For the nine months ended Sept. 29, the company reported earnings of $11.1 billion, or $4.13 a share, down from a previously reported $14.2 billion, or $5.28 a share. Adjusted earnings were not affected by the $4 billion settlement. Johnson & Johnson first reported earnings for the quarter on Oct. 15.", "description": "Johnson & Johnson Inc. said it lowered its September-ending earnings to account for opioid litigation, according to a Securities and Exchange Commission...", "authors": ["Wallace Witkowski"], "top_image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "published_at": "2019-10-23"}